Starpharma Рыночная капитализация
Что обозначает Рыночная капитализация в Starpharma?
Рыночная капитализация Starpharma Holdings Limited является $150.91M
Какое определение для Рыночная капитализация?
Рыночная капитализация - это рыночная стоимость в тот момент времени, когда акции, находящиеся в обращении публичной компании, равна цене акций в тот отрезок времени, умноженной на количество акций в обращении .
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Рыночная капитализация компаний в Health Care сектор на ASX по сравнению с Starpharma
Что делает Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Компании с рыночная капитализация похож на Starpharma
- Conns Inc имеет Рыночная капитализация из $150.73M
- Arbuthnot Banking PLC имеет Рыночная капитализация из $150.79M
- Skipper имеет Рыночная капитализация из $150.83M
- RM Secured Direct Lending Plc имеет Рыночная капитализация из $150.85M
- Desert Mountain имеет Рыночная капитализация из $150.89M
- Camellia Plc имеет Рыночная капитализация из $150.90M
- Starpharma имеет Рыночная капитализация из $150.91M
- Medallion имеет Рыночная капитализация из $151.16M
- Pix Transmissions имеет Рыночная капитализация из $151.24M
- Hostelworld Plc имеет Рыночная капитализация из $151.38M
- NWF plc имеет Рыночная капитализация из $151.41M
- Tudor Gold имеет Рыночная капитализация из $151.48M
- Loop Insights имеет Рыночная капитализация из $151.51M